Skip to content
TrialScanner

NCT04963283

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Phase 2Active, not recruitingEXELCollaboratorBMYCollaborator

Registry record

Lead sponsor
University of Colorado, Denver
Conditions
Colorectal Adenocarcinoma; Colon Cancer; Colon Adenocarcinoma; Rectum Cancer; Rectal Cancer
Primary completion
Feb 24, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04963283 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04963283: Study of Cabozantinib and... | TrialScanner